Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
Sign Up
Log in
Biotest AG banner

Biotest AG
XETRA:BIO

Watchlist Manager
Biotest AG Logo
Biotest AG
XETRA:BIO
Watchlist
Price: 40.2 EUR -4.74%
Market Cap: €1.5B
Write Note Create Alert Ask AI

Multiples-Based Value

The Multiples-Based Value of one BIO stock under the Base Case scenario is 53.53 EUR. Compared to the current market price of 40.2 EUR, Biotest AG is Undervalued by 25%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BIO Multiples-Based Value
Base Case
53.53 EUR
Undervaluation 25%
Multiples-Based Value
Price €40.2
Worst Case
Base Case
Best Case

Valuation Multiples

P/S
View Details
P/E
View Details
P/OCF
View Details
P/FCFE
View Details
P/B
View Details
EV/S
View Details
EV/GP
View Details
EV/EBITDA
View Details
EV/EBIT
View Details
EV/OCF
View Details
EV/FCFF
View Details
EV/IC
View Details

Multiples Across Competitors

BIO Competitors Multiples
Biotest AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
Biotest AG
XETRA:BIO
1.6B EUR 2.5 -64.9 182.4 182.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
374.1B USD 6.1 89.6 14.8 20.6
US
Amgen Inc
NASDAQ:AMGN
188.5B USD 5.2 24.9 14.4 14.4
US
Gilead Sciences Inc
NASDAQ:GILD
175.7B USD 6 20.8 13 16
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.8B USD 9.4 28.4 21.3 22.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82B USD 5.6 17.9 13.4 15.3
NL
argenx SE
XBRU:ARGX
41.5B EUR 11.8 37.9 40.9 41.8
AU
CSL Ltd
ASX:CSL
68.5B AUD 3 33.2 11.2 14
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
DE
Biotest AG
XETRA:BIO
Average P/S: 3 063 003.1
2.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.2
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
6
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.4
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
10%
0.6
NL
argenx SE
XBRU:ARGX
11.8
28%
0.4
AU
CSL Ltd
ASX:CSL
3
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
DE
Biotest AG
XETRA:BIO
Average P/E: 36.1
Negative Multiple: -64.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
89.6
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.9
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.8
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.4
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
13%
1.4
NL
argenx SE
XBRU:ARGX
37.9
32%
1.2
AU
CSL Ltd
ASX:CSL
33.2
10%
3.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DE
Biotest AG
XETRA:BIO
Average EV/EBITDA: 38.9
182.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.8
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
13
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.3
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.4
18%
0.7
NL
argenx SE
XBRU:ARGX
40.9
50%
0.8
AU
CSL Ltd
ASX:CSL
11.2
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DE
Biotest AG
XETRA:BIO
Average EV/EBIT: 40.8
182.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.6
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.4
3%
4.8
US
Gilead Sciences Inc
NASDAQ:GILD
16
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.3
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
23%
0.7
NL
argenx SE
XBRU:ARGX
41.8
51%
0.8
AU
CSL Ltd
ASX:CSL
14
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A

See Also

Summary
BIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
BIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BIO stock valuation using valuation multiples.
Wall Street Estimates
BIO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 329,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett